10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

EBI3 Antibody
Catalog # ASC10829

Specification

EBI3 Antibody - Product Information

Application	**WB, IHC, IF**
Primary Accession	Q14213
Other Accession	NP_005746, 14577917
Reactivity	**Human, Mouse, Rat**
Host	**Rabbit**
Clonality	**Polyclonal**
Isotype	**IgG**
Application Notes	**EBI3 antibody can be used for the detection of EBI3 by Western blot at 2 µg/mL. Antibody can also be used for immunohistochemistry starting at 2.5 µg/mL. For immunofluorescence start at 20 µg/mL.**

EBI3 Antibody - Additional Information

Gene ID	**10148**

Target/Specificity
EBI3;

Reconstitution & Storage
EBI3 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Precautions
EBI3 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

EBI3 Antibody - Protein Information

Name EBI3

Synonyms IL27B

Function
Associates with IL27 to form the IL-27 interleukin, a heterodimeric cytokine which functions in innate immunity. IL-27 has pro- and anti-inflammatory properties, that can regulate T-helper cell development, suppress T-cell proliferation, stimulate cytotoxic T-cell activity, induce isotype switching in B-cells, and that has diverse effects on innate immune cells. Among its target cells are CD4 T-helper cells which can differentiate in type 1 effector cells (TH1), type 2 effector cells (TH2) and IL17 producing helper T-cells (TH17). It drives rapid clonal expansion of naive but not memory CD4 T-cells. It also strongly synergizes with IL-12 to trigger interferon-gamma/IFN- gamma production of naive CD4 T-cells, binds to the cytokine receptor WSX-1/TCCR. Another important

role of IL-27 is its antitumor activity as well as its antiangiogenic activity with activation of production of antiangiogenic chemokines.

Cellular Location
Secreted.

EBI3 Antibody - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

EBI3 Antibody - Images



Western blot analysis of EBI3 in rat spleen tissue lysate with EBI3 antibody at 2 µg/mL.



Immunohistochemistry of EBI3 in human spleen tissue with EBI3 antibody at 2.5 µg/mL.

10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999



Immunofluorescence of EBI3 in Human Spleen cells with EBI3 antibody at 20 µg/mL.

EBI3 Antibody - Background

EBI3 Antibody: EBI3 is a subunit in two distinct heterodimeric cytokines: interleukin-27 (IL-27) and IL-35. Like interleukin-23 (IL-23), IL-27 is a recently discovered member of the IL-6/IL-12 family of proinflammatory and immunoregulatory cytokines. It exists as a heterodimer composed of the p40-related protein EBI3 and an IL-12 p35-related protein termed p28. IL-27 is produced after activation by antigen-presenting cells and induces proliferation of naïve but not memory CD4+ T-cells. It acts by binding to its receptor WSX-1 (also known as TCCR) and gp130 which results in the activation of a Jak/STAT signaling cascade, suggesting the IL-27 is involved in the regulation of immune processes. It has been suggested that IL-27 can also be used as a therapeutic agent against cancer as it can also induce tumor-specific anti-tumor activity mediated through CD8+ T-cells, IFN-gamma, and T-bet. IL-35 is composed of EBI3 and the p35 subunit of IL-12 and has been reported to have therapeutic effects against collagen-induced arthritis by expanding the population of regulatory T cells and suppressing Th17 cells. At least two isoform of EBI3 are known to exist.

EBI3 Antibody - References

Pfanz S, Timans JC, Cheung J et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naïve CD4(+) T cells. Immunity2002; 16:779-90.
Devergne O, Birkenbach M, and Kieff E. Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin form a novel heterodimeric hematopoietin. Proc. Natl. Acad. Sci. USA1997; 94:12041-6.
Niedbala W, Wei X, Cai B, et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expression of regulatory T cells and suppression of Th17 cells. Eur. J. Immunol.2007; 3021-29.
Pfanz S, Hibbert L, Mattson J, et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J. Immunol.2004; 172:2225-31.